Abnormal p53-expression and TP53 alterations were restricted to poorly differentiated neuroendocrine neoplasms, and presence of TP53 mutations correlated, in 92% of the cases, with abnormal p53-immunolabeling [7]. This evidence concerns the gene TP53 and neuroendocrine neoplasm.